Sanofi is creating a stir: Sanofi will serve the United States first if it finds a vaccine against the new coronavirus, the laboratory says. Why such a commitment? Because the country “Share the risk” research carried out through a partnership, said the director general of the French laboratory Paul Hudson at the Bloomberg agency, Wednesday, May 13. The American government “Has the right to the biggest pre-orders”added Paul Hudson.
They (the United States, editor’s note) “Get the vaccines first”, continued the boss of the laboratory, because “They have invested to try to protect their population”. An advance that will be a few days or weeks on the rest of the world, he said.
A declaration which immediately provoked a strong reaction on the French side. “For us, it would be unacceptable if there were privileged access from such or such country under a pretext which would be a financial pretext”, Secretary of State for the Economy Agnès Pannier-Runacher, said on Thursday May 14 on Sud Radio.
“Sanofi has a diversified and international industrial base. We have production capacities in the United States, in Europe, especially in France and elsewhere in the world. Production on American soil will be mainly dedicated to the United States and the rest of our production capacity will be allocated to Europe, France and the rest of the world. “, Sanofi had further specified in an evening statement on Wednesday May 13. “We have always made a commitment that in these unprecedented circumstances, our vaccine will be accessible to all”, added the laboratory.
– Sanofi France (@SanofiFR) May 13, 2020
“The cooperation established with Barda (Authority for advanced research and development in the biomedical field) in the United States allows to start the production of the vaccine as quickly as possible in parallel with the development and registration of the vaccine”, according to the laboratory which welcomes “Encouraging progress for several weeks by the mobilization of the European Commission to consider similar measures and accelerate the development of vaccines and the availability to European citizens”.
“Very constructive discussions” with Europe, France and Germany
“We are having very constructive discussions with the European institutions as well as with the French and German governments”, he said. Sanofi, one of the world’s leading vaccine specialists, launched the race against the new coronavirus in mid-February, with the announcement of a cooperation agreement with the Barda Authority, which reports to the United States Department. of health.
→ INFOGRAPHY. Coronavirus: the slow and difficult manufacture of a vaccine
Sanofi will use its recombinant DNA technology to “Accelerate the development of a potential Covid-19 vaccine”, he indicated then. To this end, the group has allied with the British GSK, through a collaboration in which the two laboratories hope to obtain a result by 2021.